vs
Side-by-side financial comparison of Prelude Therapeutics Inc (PRLD) and Zhibao Technology Inc. (ZBAO). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $4.1M, roughly 1.6× Zhibao Technology Inc.). Zhibao Technology Inc. runs the higher net margin — -2.1% vs -303.5%, a 301.4% gap on every dollar of revenue. On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs -79.7%).
PRLD vs ZBAO — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $6.5M | $4.1M |
| Net Profit | $-19.7M | $-85.5K |
| Gross Margin | — | 34.8% |
| Operating Margin | -314.1% | 2.2% |
| Net Margin | -303.5% | -2.1% |
| Revenue YoY | 116.7% | -79.7% |
| Net Profit YoY | 38.9% | 3.2% |
| EPS (diluted) | $-0.26 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $4.1M | ||
| Q3 25 | $6.5M | — | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | $3.0M | — | ||
| Q4 23 | — | $11.9M |
| Q4 25 | — | $-85.5K | ||
| Q3 25 | $-19.7M | — | ||
| Q4 24 | — | $-88.3K | ||
| Q3 24 | $-32.3M | — | ||
| Q4 23 | — | $-1.2M |
| Q4 25 | — | 34.8% | ||
| Q3 25 | — | — | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | — | — | ||
| Q4 23 | — | 35.7% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | -314.1% | — | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -1145.9% | — | ||
| Q4 23 | — | -9.9% |
| Q4 25 | — | -2.1% | ||
| Q3 25 | -303.5% | — | ||
| Q4 24 | — | -0.4% | ||
| Q3 24 | -1075.7% | — | ||
| Q4 23 | — | -10.1% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.26 | — | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | $-0.43 | — | ||
| Q4 23 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.0M | $3.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.5M | $6.8M |
| Total Assets | $94.8M | $39.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.8M | ||
| Q3 25 | $55.0M | — | ||
| Q4 24 | — | $3.9M | ||
| Q3 24 | $153.6M | — | ||
| Q4 23 | — | $779.8K |
| Q4 25 | — | $6.8M | ||
| Q3 25 | $58.5M | — | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | $156.4M | — | ||
| Q4 23 | — | $2.2M |
| Q4 25 | — | $39.1M | ||
| Q3 25 | $94.8M | — | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | $197.2M | — | ||
| Q4 23 | — | $33.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.1M | $-241.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-241.5K | ||
| Q3 25 | $-19.1M | — | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | $-27.3M | — | ||
| Q4 23 | — | $12.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-27.4M | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -912.0% | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.1% | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
